8-K: Orgenesis Acquires Spinal Cord Injury Therapy Assets from Neurocords in Stock Deal

Orgenesis Inc. has acquired intellectual property assets related to spinal cord injury therapies from Neurocords, LLC in exchange for common stock and the termination of previous agreements.

Summary

• Orgenesis Inc. acquired certain intellectual property assets and related development products for spinal cord injury therapies from Neurocords, LLC.
• The acquisition was completed on March 3, 2025, following an agreement signed on February 28, 2025.
• As consideration, Orgenesis will issue 1,200,000 shares of its common stock to Neurocords, which will be free of trading restrictions after a 6-month period.
• The agreement also includes mutual releases of all future claims and the termination of prior licensing and related agreements between the two companies.
• Orgenesis also secures a three-month option to acquire the William Rice University Option Agreement at no additional cost.
• The common stock of Orgenesis began trading on the OTCQX operated by the OTC Markets Group, Inc. beginning on October 21, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Orgenesis is expanding its portfolio in a promising area, but the delisting from Nasdaq and stock dilution are potential concerns.

Positives

• Orgenesis gains access to intellectual property and development assets in the field of spinal cord injury therapies.
• The acquisition simplifies the relationship between Orgenesis and Neurocords by terminating previous agreements and settling disputes.
• The structure of the deal, using stock, may conserve Orgenesis' cash resources.
• Orgenesis secures an option to acquire additional assets related to the William Rice University Option Agreement.

Negatives

• Orgenesis is issuing 1,200,000 shares of its common stock, which could dilute existing shareholders.
• The company's stock is transitioning to the OTCQX market after being delisted from Nasdaq, which may affect liquidity and investor perception.
• The value of the acquired assets is not explicitly stated, making it difficult to assess the financial impact of the acquisition.

Risks

• The success of the acquired spinal cord injury therapies is uncertain and depends on future development and regulatory approvals.
• The transition to the OTCQX market could negatively impact the company's stock price and trading volume.
• The 1,200,000 share issuance could dilute existing shareholders and put downward pressure on the stock price.
• There is a risk that the acquired assets may not generate the expected returns or synergies for Orgenesis.

Future Outlook

Orgenesis will evaluate whether it wishes to receive Asset # 4 from Neurocords or Malik during a three-month option period, which will expire three months following the Closing Date.

Industry Context

The acquisition reflects a continued interest in regenerative medicine therapies, particularly for spinal cord injuries, which represents a significant unmet medical need. Companies are actively seeking innovative solutions in this area, and Orgenesis' acquisition positions them to potentially capitalize on this growing market.

Comparison to Industry Standards

• It is difficult to compare this specific asset acquisition to industry standards without knowing the specific details of the intellectual property and its potential market value.
• However, similar acquisitions in the biotech and pharmaceutical industries often involve upfront payments, milestone payments, and royalties based on future sales.
• The use of stock as consideration is common, especially for smaller companies or those looking to conserve cash.
• Comparable companies in the regenerative medicine space include companies such as Vertex, CRISPR Therapeutics and Editas Medicine, which are developing gene-editing therapies for various diseases.

Stakeholder Impact

• Shareholders will experience potential dilution from the issuance of new shares.
• Employees may see new opportunities within Orgenesis as the company expands its research and development efforts.
• Patients with spinal cord injuries may benefit from the development of new therapies resulting from the acquisition.
• Neurocords will become a shareholder of Orgenesis and will no longer be involved in the development of the acquired assets.

Next Steps

• Orgenesis will integrate the acquired assets into its existing research and development programs.
• Orgenesis will evaluate and decide whether to exercise its option to acquire the William Rice University Option Agreement within the next three months.
• Orgenesis will manage the transition of its stock trading to the OTCQX market.

Key Dates